Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Takeda to Reshuffle Global Structure in April
September 18, 2014
- Toray Partners with German Firm on Sales of Hemoperfusion Device in Europe
September 18, 2014
- Allergan, Shionogi Tie Up for Sales of Eyelash Hypotrichosis Agent
September 18, 2014
- Bayer Paid 10.1 Billion Yen to Healthcare Professionals in 2013
September 18, 2014
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
- Eli Lilly, AstraZeneca to Codevelop BACE Inhibitor for AD Treatment
September 18, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
- Novartis Files Jakavi for Polycythemia Vera in Japan
September 17, 2014
- Nippon Shinyaku to Gear Up R&D, Commercialization of Nucleic Acid Products
September 17, 2014
- Takeda Picks Teva’s Gerard Greco as Global Quality Officer
September 17, 2014
- Sanofi Taps Call Center to Prevent Patient Dropouts from Insulin Therapy
September 16, 2014
- Pharmacy Chains Hurrying to Reach Price Settlements with Wholesalers ahead of Sept.-End Deadline
September 16, 2014
- Novartis Pharma Paid 22.9 Billion Yen to Healthcare Professionals in 2013
September 16, 2014
- AstraZeneca’s 2013 Payments to Healthcare Professionals Reach 7.5 Billion Yen
September 16, 2014
- JB, MTPC to Cease Sales Collaboration for Plasma Products in March 2015
September 16, 2014
- Takara Bio Pushes for Melanoma Drug Development with Eye on Fast Approval
September 12, 2014
- Shionogi Paid 15.2 Billion Yen to Medical Institutions in FY2013
September 12, 2014
- LEO Pharma Launches Its 1st Product in Japan, with Kyowa Kirin as Distributor
September 12, 2014
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…